Notably, we found that WFDC1 expression was particularly elevated in patients with the RUNX1-RUNX1T1 fusion, suggesting its potential role as a subtype-specific biomarker or therapeutic target in this AML subgroup. The gene discussed is RUNX1; the disease is acute myeloid leukemia.